An arginine vasopressin analogue, desmopressin is frequently used for MNE treatment. In a large portion of children with MNE, nocturnal polyuria is seen due to an abnormal circadian release of vasopressin (
33). In children with MNE, desmopressin is the second-line treatment option after alarm therapy (
25). One study demonstrated the importance of the balance between bladder capacity and nocturnal urine output in children with MNE. In this study, nocturnal urine production was distinctly lower during dry nights under desmopressin treatment compared to untreated wet nights (
34). The sudden and inappropriate discontinuation of desmopressin results in high recurrence of enuresis (
35) although planned discontinuations have been demonstrated to have low relapse rates (
36). Response to treatment is 60 - 70% although some studies have shown a relapse rate as high as 50 - 90% (
35,
37). Bradbury et al. reported that the addition of oxybutynin to desmopressin not only increased the success rate, but also decreased the relapse rate (
38). Desmopressin is available in tablet or nasal spray form, and its effects last for up to 12 hours after a dose is taken. Its important side effects include headache, nasal congestion, nosebleeds, abdominal cramps, water intoxication, allergic reactions, hyponatremia, anorexia, nausea, bad taste in mouth, and problems with vision (
39).